IGF-1 DES
Also known as: Des(1-3) IGF-1, IGF-1 Des 1-3
Truncated IGF-1 Analog | Localized Muscle Growth
Overview
IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.
Key benefits
- Approximately 10x more potent than native IGF-1
- 100% bioactive -- does not bind to IGF binding proteins
- Extremely short half-life enables localized, site-specific action
- Promotes satellite cell activation for muscle hyperplasia
- Minimal systemic exposure compared to IGF-1 LR3
Mechanism of action
IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.
Molecular data
- Type
- Truncated IGF-1 analog
- Half-life
- 20-30 minutes
Indications
What the research community uses this compound for, with self-reported effectiveness.
Muscle Growth
Tissue Repair
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 20-30mcg | Post-workout, injected into trained muscle | — |
| — | 30-50mcg | Post-workout, injected into trained muscle | — |
| — | 50mcg | Post-workout, split across multiple trained muscles | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Hypoglycemia -- consume carbohydrates after injection
- Localized swelling and soreness at injection site
- Increased pump in targeted muscles
- Mild lightheadedness shortly after injection
Contraindications
- Not approved for human use -- research chemical only
- Cancer history or active malignancy (IGF-1 promotes cell proliferation)
- Diabetes or impaired glucose regulation
- WADA prohibited substance -- causes failed drug tests
Monitoring
- Consume 20-40g fast carbohydrates immediately after each injection
- Monitor blood glucose, especially during the first week
- Rotate injection sites to avoid localized fibrosis
- Limit cycles to 4-6 weeks with equal off-time
- Watch for disproportionate growth in frequently targeted muscles
References
Primary literature and clinical-trial data informing this entry.